The Valuation Re-Frame: From Consumer Diet Drug to Sovereign Infrastructure Behind closed doors in institutional roundtables and private family office briefings, a fundamental valuation shift has occurred. The early narrative—dominated by direct-to-consumer weight-loss telehealth, consumer hype, and simple scale metrics—has run its course. Institutional allocators are now evaluating incretin receptor agonists through a far more rigorous lens: multi-systemic geroprotective pl

THE HORIZONS Dispatch | Oct - Nov 06 Mapping the future of healthspan capital, brainspan innovation, and luxury infrastructure across Europe, Asia, the Middle East, and beyond.

Direct macro intelligence synthesized from main-stage keynotes and private allocator dialogues at the seventh Longevity Investors Conference in Gstaad. What Top Allocators at the Longevity Investors Conference Are Quietly Rotating Out Of—and the Sovereign Infrastructure Replacing It.

Oura Inc. (Nasdaq: OURA) sets its public market debut for the week of September 28, 2026, offering 50 million shares priced between $40.00 and $44.00 to target a fully diluted valuation of $15.62 billion. Revenue scaled to $1.21 billion for the nine months ending June 30, 2026 (+74% YoY), driving a net income inflection to $60.8 million alongside expanding recurring SaaS margins.

Capital follows vitality. Here is where the global longevity, investment, and high-performance ecosystem meets next.

Capital follows vitality. Here is where the global longevity, investment, and high-performance ecosystem meets next.

The field has moved fast. Not long ago longevity was treated as a curiosity; now Longevity's a real investment category, on track to reach $67B by 2035. That shift is the thing worth paying attention to. The good companies aren't selling immortality. They're going after healthspan, treating aging as a root cause, and measuring themselves against clinical results.

Executive Summary The Event: Global venture capital firm QAI Ventures launches Singapore’s inaugural Quantum Accelerator in partnership with Enterprise Singapore, deploying an initial SGD 300,000 capital package per deep-tech venture. The Thesis: Quantum computing represents the definitive backend infrastructure for the luxury longevity economy. The transition from basic discovery to biological engineering requires processing capacities capable of bypassing legacy lab

Executive Summary The Event: ŌURA acquires Galen AI, a Y Combinator-backed startup specializing in AI-powered aggregation of medical records, lab results, medications, and wearable data into a unified interface. The Thesis: The longevity economy is shifting from wearable devices to integrated Health Intelligence Platforms — where AI, biometrics, and longitudinal clinical data converge into a continuous operating system for preventive health.

L Catterton, the private equity fund backed by LVMH and Groupe Arnault, has invested up to US$5 million in WTHN, the New York-based brand that modernises Traditional Chinese Medicine (TCM) through a clean, design-led luxury model.